Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2011 / Cilt: 20 - Sayı: 1

Octreotide may prevent ultrafiltration failure in experimental peritonitis model

Deneysel peritonit modelinde oktreotid ultrafiltrasyon yetmezliğini engelleyebilir

Pages
46–52
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the long-term, it can decrease peritoneal fibrosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Ultrafiltration (UF) failure is a frequent complication of peritoneal dialysis peritonitis.
📊
Key Findings & Data:The present study aimed to investigate the effect of OCT (administered locally or systemically) on peritoneal alterations induced by bacterial peritonitis.MATERIAL and METHODS: Forty-two non-uremic female rats, weighing 160-180 g, were divided into four groups receiving no treatment (Control, n=12), peritonitis group (received 1.5 ml suspension of E. coli (107 CFU/ml) (E.coli, n=12)), and two treatment groups that received E.coli + 50 mcg/kg OCT (local OCT, n=10) intraperitoneally (IP) and (systemic OCT, n=8) subcutaneously.
💡
Conclusion & Impact:In the long-term, it can decrease peritoneal fibrosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Ultrafiltration (UF) failure is a frequent complication of peritoneal dialysis peritonitis. Octreotide (OCT) has antiproliferative effects on many cells. The present study aimed to investigate the effect of OCT (administered locally or systemically) on peritoneal alterations induced by bacterial peritonitis.MATERIAL and METHODS: Forty-two non-uremic female rats, weighing 160-180 g, were divided into four groups receiving no treatment (Control, n=12), peritonitis group (received 1.5 ml suspension of E. coli (107 CFU/ml) (E.coli, n=12)), and two treatment groups that received E.coli + 50 mcg/kg OCT (local OCT, n=10) intraperitoneally (IP) and (systemic OCT, n=8) subcutaneously. After six hours, a one-hour PET was performed with 20 ml 3.86% PD solution; the D1/D0 glucose, UF volume, dialysate cell count, dialysate protein, TGF-β1, VEGF and IL-1β levels were determined.RESULTS: Exposure to E. coli causes bacterial peritonitis with increase in peritoneal permeability leading to rapid dissipation of the glucose gradient and UF failure. IP administration of OCT led to attenuation of UF failure by inhibiting local TGF-β1 production. Both local and systemic administration of OCT decreased dialysate cell count and maintained UF.CONCLUSION: Local or systemic OCT administration may help to preserve peritoneal viability and UF capacity by inhibiting cell infiltration to the peritoneal cavity and decreasing dialysate cell count during peritonitis. In the long-term, it can decrease peritoneal fibrosis.

Özet

AMAÇ: Ultrafiltrasyon (UF) yetersizliği periton diyalizi peritonitinde sık rastlanan bir komplikasyondur. Oktreotid (OCT)' in birçok hücre üzerinde antiproliferatif etkileri olduğu gösterilmiştir. Bu çalışmada amacımız, bakteriyel peritonitin neden olduğu periton değişiklikleri üzerine sistemik veya bölgesel olarak uygulanan OCT' nin etkilerini incelemektir.GEREÇ ve YÖNTEMLER: Kırk iki tane üremik olmayan 160-180 gr ağırlığında dişi sıçan; Tedavi verilmeyen grup (Kontrol, n=12), Peritonit grubu (E.coli, n=12) 1,5 ml E. coli suspansiyonu (107 CFU/ml), Tedavi grupları 1,5 ml E. coli suspansiyonu (107 CFU/ml)+ 50mcg/kg OCT periton içine (Bölgesel OCT, n=10) ve deri altına (Sistemik OCT, n=8) uygulanmak suretiyle dört gruba ayrıldı. Altı saat sonunda, %3,86 glukoz içeren PD solusyonu ile bir saatlik periton eşitlenme testi yapıldı. D1/D0 glukoz, UF hacmi, diyalizat hücre sayısı, diyalizat protein, TGF-β1, VEGF ve IL-β düzeyleri ölçüldü.BULGULAR: E. coli maruziyeti bakteriyel peritonite yol açarak periton geçirgenliğini artırıp glukoz gradiyentinde azalma ve UF yetmezliğine neden oldu. Periton içine uygulanan OCT bölgesel TGF-β1 inhibisyonu ile UF yetmezliğini azaltmıştır. Bölgesel ve sistemik olarak uygulanan OCT diyalizat hücre sayısını azaltmış ve UF' yi korumuştur.SONUÇ: Bölgesel ve sistemik olarak uygulanan OCT peritonit sırasında diyalizat hücre sayısını azaltarak, periton boşluğuna hüce infiltrasyonunu inhibe etmek suretiyle UF kapasitesini ve periton canlılığını korumaya yardım ediyor olabilir. Uzun dönemde peritoneal fibrozisi azaltabilir.

🔖

Cite This Article

DUMAN, C., AKÇİÇEK, F., DUMAN, S., HÜR, E., ARDA, B., ŞEN, S., SİPAHİ, S., BAŞÇI, A., BOZKURT, D., ERTİLAV, M. (2022). Octreotide may prevent ultrafiltration failure in experimental peritonitis model. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 20 - Sayı: 1, 46–52. https://ajindex.com/articles/636424

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Krediet RT: The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999; 55: 341-356 2. Tzamaloukas AH: Inadequacy of dialysis and infectious complications of continuous ambulatory peritoneal dialysis (CAPD): Diagnosis, management and prevention. AKF Nephrol 1991; 8:29 3. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, Kawaguchi Y, Kawanishi H, Korbet S, Krediet R, Lindholm B, Oreopoulos D, Rippe B, Selgas R: Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 Suppl 4: S5-21 4. Pollock CA, Ibels LS, Hallett MD: Loss of ultrafiltration in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9: 107 5. Margetts PJ, Churchill DN: Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 2002; 13: 2787 6. Stegmayr BG: Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. Perit Dial Int 1997; 17: 541 7. Honda K, Nitta K, Horita S, Yumura W, Nihei H: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-176 8. Rubin J, Herrera GA, Collins D: An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18: 97-102 9. Fracasso A, Baggio B, Ossi E, Prete DD, Bonfante L, Bazzato G, Gambaro G: Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33: 105-110 10. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549-74 11. Krediet RT, Zuyderhoudt FM Krediet R, Mujais S: Use of icodextrin in high transport ultrafiltration failure. Kidney Int 2002; (81): S53-61 12. Boeschoten EW, Arisz L: Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 1987; 17: 43-52 13. Douma CE, de Waart DR, Struijk DG, Krediet RT: Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis? J Lab Clin Med 1998; 132: 329-340 14. Panneke